Clinical Trials Logo

Fetal Alcohol Spectrum Disorders clinical trials

View clinical trials related to Fetal Alcohol Spectrum Disorders.

Filter by:

NCT ID: NCT03852550 Terminated - Epilepsy Clinical Trials

READYorNot[TM] Brain-Based Disabilities Trial

Start date: June 22, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to find out if there is a benefit to using the MyREADY Transition[TM] BBD App for brain-based disabilities, compared to not using it. To do this, some of the participants in this study will use the MyREADY Transition[TM] BBD App and others will not use the App. Everyone will continue to get the same care they have been getting (their usual care). The study team wants to see how youth will use the MyREADY Transition[TM] BBD App as they are getting ready to leave the children's hospital or children's treatment centre. And, they want to see if it will help youth to be knowledgeable about their own health. The study team hopes to see youth taking steps to develop the skills so they become better managers of their health. For example, this would include knowing about their medication or knowing when to ask for help from parents/caregivers and health care providers.

NCT ID: NCT03802708 Completed - Clinical trials for Fetal Alcohol Spectrum Disorder

Fetal Alcohol Spectrum Disorder-Is This a Ciliopathy?

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

Urine sample and exhaled Nitric Oxide will analyzed and compared between children diagnosed with Fetal Alcohol Spectrum Disorder and healthy control. Pilot study- 5 children in each group

NCT ID: NCT03782935 Completed - Clinical trials for Fetal Alcohol Spectrum Disorders

Nutritional Risk Factors for FASD in Ukraine

Start date: June 2006
Phase: N/A
Study type: Interventional

Interventional study randomizing pregnant women at two sites in Ukraine who have or have not already consumed moderate to heavy levels of alcohol in pregnancy to receiving a standard prenatal vitamin supplement with or without additional choline supplement or standard of care (recommendation to take vitamin supplements) through the remainder of pregnancy, and to compare neurobehavioral performance of the offspring on the Bayley Scales of Infant Development at 12 months of age between groups. The overall sample size target was 300 alcohol exposed and 300 low or unexposed across both sites.

NCT ID: NCT03524664 Completed - Clinical trials for Fetal Alcohol Spectrum Disorders

A Study of Parent and Child Emotions in Fetal Alcohol Spectrum Disorder (FASD)

Start date: August 13, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to learn about the emotion regulation skills of children with fetal alcohol spectrum disorders (FASD) and different strategies that may improve these skills. This study is also testing whether a training program taught to caregivers is helpful. Children will be asked to: - Complete a brief measure of verbal and nonverbal problem-solving skills. - Play two computer games. - Have their heart rate measured while completing a task that is designed to be mildly disappointing. Two ECG pads are placed on the chest with a small recorder. - Play or relax with study staff while you are finishing caregiver activities. Caregivers will be asked to complete interviews and questionnaires about: - the child's background, including any past stressful experiences - the child's behavior and how s/he handles emotions - caregiver views on the child's emotions and their own - caregiver relationship with the child - Stress caregivers experience as a parent

NCT ID: NCT03494738 Active, not recruiting - Clinical trials for Fetal Alcohol Spectrum Disorders

Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder

Start date: April 12, 2018
Phase:
Study type: Observational

The objective of the study is to validate epigenetic changes as biomarkers in a prospective sampling of newborn blood samples collected at birth (umbilical cord blood) and during routine screening (heel stick blood) in newborns concurrently tested for alcohol exposure levels by PEth blood spot testing.

NCT ID: NCT03371641 Recruiting - Clinical trials for Fetal Alcohol Syndrome

In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions

ALCOBRAIN
Start date: January 27, 2017
Phase: N/A
Study type: Interventional

This study aims to validate that PLGF is a biomarker of cerebral lesions and therefore of secondary developmental disorders and disabilities that will be best diagnosed at 2 and 6 years of age.

NCT ID: NCT03361293 Completed - Clinical trials for Fetal Alcohol Spectrum Disorders

Cognitive Training and tDCS for Children With FASD

Start date: November 20, 2017
Phase: N/A
Study type: Interventional

This is a randomized placebo-controlled trial of cognitive training with transcranial direct current stimulation (tDCS) for children and adolescents (ages 10 - 16 years) with prenatal alcohol exposure (PAE).

NCT ID: NCT03342495 Completed - Stroke Clinical Trials

Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial

TNT
Start date: February 6, 2018
Phase: N/A
Study type: Interventional

The Transition Navigator Trial (TNT) is a pragmatic randomized controlled trial evaluating the effectiveness of usual care plus a patient navigator service versus usual care plus newsletters and other educational materials, to improve transition outcomes among adolescents aged 16-21 who have chronic health conditions requiring transfer to adult specialty care. The study will provide urgently needed data to guide health care providers and policy makers regarding the provision of coordinated transition care. These results have the potential to: 1. Change care delivery 2. Improve health outcomes 3. Improve the experiences of young adult transition to adult care

NCT ID: NCT02912962 Completed - Adolescents Clinical Trials

Self-Regulation in Adolescents With FASD: The Efficacy of a Targeted Intervention

Start date: September 2016
Phase: N/A
Study type: Interventional

Fetal alcohol spectrum disorder (FASD) describes a collection of physical, mental, and behavioral disabilities that result from prenatal alcohol exposure (PAE). Individuals with FASD often struggle with self-regulation, or the ability to control thoughts, emotions and actions, which can lead to many long-term problematic life circumstances. This study aims to improve self-regulation abilities in adolescents, aged 11-17, with FASD using a targeted intervention. Researchers adapted the Alert Program®, a developed intervention targeting self-regulation in children, to be appropriate for an adolescent FASD population. Participants are split into two groups: an FASD intervention group, and an FASD waitlist group. These groups are compared on a variety of measures. These measures include cognitive measures (executive functioning, response conflict, inhibitory control, etc), behavioural measures (self-regulation, adaptive behaviour, etc), and physiological measures (cortisol and sleep). The FASD intervention group will be tested at baseline and once after the intervention, and lastly after an approximately 12-week wait following the intervention. The FASD waitlist group will be tested at baseline, after a three month wait period, and again after receiving the intervention. The investigators expect that the Alert program® will lead to significant improvements in participant's self-regulation abilities as evidenced by cognitive, behavioural, and physiological changes. Improving self-regulation in adolescents with FASD will reduce the high level of adverse outcomes experienced by adolescents with FASD, and help them have a successful transition into adulthood.

NCT ID: NCT02759874 Enrolling by invitation - Pregnancy Clinical Trials

Prevention of Fetal Alcohol Spectrum Disorder (FASD) by the Use of Technology

Start date: November 2015
Phase: N/A
Study type: Interventional

The Institute of Health Economics is conducting a study to determine how a breathalyzer linked to a cloud based alcohol monitoring system changes alcohol consumption during pregnancy in women with alcohol dependency issues. IHE posits that the ability to self-monitor blood alcohol concentration and the ability to share sobriety via email or text with loved ones and counselors may reduce alcohol consumption and thus reduce the possibility of delivering a child with FASD. The study will provide useful evidence for tailoring future optimal maternal and child healthcare for women, with the potential of decreasing healthcare utilization by prevention of FASD. Breathalyzer device usage plus secure document sobriety should improve patient monitoring convenience and demonstrate reductions in alcohol use outside of traditional office visits and patient self-reports.